Capricor Therapeutics CAPR Receivable from credits from ARPA
Receivable from credits from ARPA at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GrantsReceivableCurrent.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's receivable from credits from arpa.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's receivable from credits from ARPA?
- Capricor Therapeutics (CAPR) reported receivable from credits from ARPA of $0 in Q1 2026.
- How has Capricor Therapeutics's receivable from credits from ARPA changed year-over-year?
- Capricor Therapeutics's receivable from credits from ARPA decreased by 100.0% year-over-year, from $59.83K to $0.
- What does receivable from credits from ARPA mean?
- This metric represents the current portion of funds due to the company from government agencies or public institutions under research and development grant agreements. It reflects the value of services performed or milestones achieved for which payment has been earned but not yet received. This asset is critical for assessing the company's short-term liquidity and the reliability of its non-dilutive funding sources.